| P/E (FY) | 30.1 | Sales (TTM) | $1.55B |
| Earnings (TTM) | $279.0M | ROE | 21.45% |
| Net Margin | 15.15% | ROIC | 50.98% |
| Debt / Equity | 0.00 | TD / EBITDA | 0.00 |
| EPS Growth 3Y | 104.28% | Sales Growth 3Y | 18.13% |
Lantheus Holdings develops, manufactures, and commercializes diagnostic and therapeutic products that assist in diagnosing and treating heart disease, cancer, and other conditions worldwide. Its products include DEFINITY, an injectable ultrasound enhancing agent, TechneLite technetium generators, Xenon-133, Neurolite, Cardiolite, and PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer. It also provides the Automated Bone Scan Index for assessing disease burden.
| Market Cap | $6.68B | Trading Days | 2786 |
| 52W High | 111.86 |
| 52W Low | 47.25 |
| % Off High | −8.24% |
| YTD | 54.23% | 1Y | 41.75% |
| 3Y | 16.70% | 5Y | 280.01% |
| 10Y | 2315.06% | Since incept. (ann.) | 27.78% |
US 95% · Non Us 5%
| Ann. Volatility (1Y) | 47.38% | Ann. Volatility (3Y) | 56.29% |
| Sharpe (1Y) | 1.00 | Sharpe (3Y) | 0.40 |
| Max Drawdown (1Y) | −31.01% | Max Drawdown (3Y) | −59.46% |
| Beta (3Y, vs SPY) | 0.17 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CLDX | Celldex Therapeutics, Inc. | $2.79B | — |
| NEOG | NEOGEN CORP | $2.00B | — |
| NTLA | Intellia Therapeutics, Inc. | $1.52B | — |
| QDEL | QuidelOrtho Corp | $1.14B | — |
| IDXX | IDEXX LABORATORIES INC /DE | $44.93B | 43.5 |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $634.4M | — |
| MYGN | MYRIAD GENETICS INC | $502.5M | — |
| TKNO | Alpha Teknova, Inc. | $260.0M | — |
| IMDX | Insight Molecular Diagnostics Inc. | $148.9M | — |
| ICCC | IMMUCELL CORP /DE/ | $101.7M | — |
| QCLS | Q/C TECHNOLOGIES, INC. | $25.3M |
| — |
| BMRA | BIOMERICA INC | $4.9M | — |